# Efficacy of Thrice Weekly Directly Observed Treatment, Short-course (DOTS) in HIV-associated Tuberculosis

> **NCT00698334** · PHASE3 · COMPLETED · sponsor: **All India Institute of Medical Sciences** · enrollment: 150 (estimated)

## Conditions studied

- HIV Infections
- Acquired Immunodeficiency Syndrome
- Tuberculosis

## Interventions

- **DRUG:** INH, Rifampicin, Ethambutol and Pyrazinamide
- **DRUG:** INH, Rifampicin, Ethambutol and Pyrazinamide

## Key facts

- **NCT ID:** NCT00698334
- **Lead sponsor:** All India Institute of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2010-09
- **Final completion:** 2011-04
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2011-11-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00698334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00698334, "Efficacy of Thrice Weekly Directly Observed Treatment, Short-course (DOTS) in HIV-associated Tuberculosis". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00698334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*